The UK Competition Authority initiates proceedings in the High Court seeking the disqualification of seven directors in connection with its decision on illegal market sharing arrangements for the supply of Prochlorperazine tablets (Alliance Pharmaceuticals / Focus / Lexon / Medreich)

Through a pattern of recent enforcement action, the UK Competition and Markets Authority ("CMA") has sent a clear message to business: it will not hesitate to hold senior management personally liable for competition law infringements. As a matter of policy the CMA is increasingly determined to deter cartel participation by combining substantial corporate fines with the individual prosecution of culpable directors. Emboldened by recent court victories, described below, in November 2022 the CMA issued proceedings in the UK High Court seeking the disqualification of seven directors in connection with illegal market sharing arrangements relating to the supply of Prochlorperazine tablets in the UK. In February 2022, the CMA had, in relation to the same infringement, imposed fines totalling